Is ATXS or EQR a better dividend investment in 2026?

ATXS currently yields 15.90% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: ATXS offers higher current income.

What is the dividend yield difference between ATXS and EQR?

ATXS has a forward dividend yield of 15.90% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 10.03 percentage points.

Home › Compare › ATXS vs EQR

ATXS vs EQR: Dividend Comparison 2026

ATXS yields 15.90% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ATXS wins by $8.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ATXS

● Live price

15.90%

Share price

$12.58

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.6K

Annual income

$4,231.63

Full ATXS calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — ATXS vs EQR

📍 ATXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ATXS	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ATXS + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ATXS pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATXS

Annual income on $10K today (after 15% tax)

$1,351.35/yr

After 10yr DRIP, annual income (after tax)

$3,596.89/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, EQR beats the other by $1,057.38/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATXS + EQR for your $10,000?

ATXS: 50%EQR: 50%

100% EQR50/50100% ATXS

Portfolio after 10yr

$52.2K

Annual income

$4,853.62/yr

Blended yield

9.30%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ATXS

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$13.00

+3.3% upside vs current

Range: $13.00 — $13.00

Altman Z

6.6

Piotroski

3/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATXS buys

EQR buys

No recent congressional trades found for ATXS or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricATXSEQR

Forward yield	15.90% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$56.6K ✓	$47.8K
Annual income after 10y	$4,231.63	$5,475.61 ✓
Total dividends collected	$28.3K ✓	$23.0K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Hold	Hold
Analyst price target	$13.00	$70.35 ✓

Year-by-year: ATXS vs EQR ($10,000, DRIP)

Year	ATXS Portfolio	ATXS Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$12,290	$1,589.83	$11,380	$679.82	+$910.00 → ATXS
2	$14,976	$1,826.04	$13,014	$837.25	+$2.0K → ATXS
3	$18,104	$2,079.61	$14,961	$1,036.20	+$3.1K → ATXS
4	$21,721	$2,349.50	$17,297	$1,289.22	+$4.4K → ATXS
5	$25,876	$2,634.46	$20,121	$1,613.15	+$5.8K → ATXS
6	$30,620	$2,933.08	$23,561	$2,030.84	+$7.1K → ATXS
7	$36,007	$3,243.80	$27,783	$2,573.54	+$8.2K → ATXS
8	$42,093	$3,564.96	$33,013	$3,284.39	+$9.1K → ATXS
9	$48,934	$3,894.82	$39,547	$4,223.51	+$9.4K → ATXS
10	$56,591	$4,231.63	$47,791	$5,475.61	+$8.8K → ATXS

ATXS vs EQR: Complete Analysis 2026

ATXS — Stock

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Full ATXS Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this ATXS vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATXS vs SCHD ATXS vs JEPI ATXS vs O ATXS vs KO ATXS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.